{"pmid":32341229,"title":"Saudi association for the study of liver diseases and transplantation position statement on liver transplantation during the COVID-19 pandemic.","text":["Saudi association for the study of liver diseases and transplantation position statement on liver transplantation during the COVID-19 pandemic.","The World Health Organization (WHO), on March 11(th) 2020, upgraded the status of the novel coronavirus disease (COVID-19) from epidemic to pandemic. Over two million individuals have been infected with SARS-CoV-2, the virus causing COVID-19, and as of April, 14(th) 2020, there were over 5000 confirmed cases in Saudi Arabia (SA). Many countries, including SA, have imposed major restrictions on travel, and everyday life, and the implications of these necessary changes are being felt in liver transplant (LT) centers in SA. Concerns remain that there is an increased risk for individuals over 65 years of age, with underlying medical conditions, or for those who are immunocompromised. Therefore, the Saudi Association for the Study of Liver Diseases and Transplantation (SASLT) established an urgent task force to launch a statement that can be utilized by LT centers as a guidance in the management of patients with advanced liver disease from the time of LT listing to the post-operative care of transplanted patients.","Saudi J Gastroenterol","Al-Judaibi, Bandar","Almaghrabi, Reem","Alghamdi, Mohammed","Al-Hamoudi, Waleed K","AlQahtani, Mohammed","Abaalkhail, Faisal","Shagrani, Mohammed","Sanai, Faisal M","32341229"],"abstract":["The World Health Organization (WHO), on March 11(th) 2020, upgraded the status of the novel coronavirus disease (COVID-19) from epidemic to pandemic. Over two million individuals have been infected with SARS-CoV-2, the virus causing COVID-19, and as of April, 14(th) 2020, there were over 5000 confirmed cases in Saudi Arabia (SA). Many countries, including SA, have imposed major restrictions on travel, and everyday life, and the implications of these necessary changes are being felt in liver transplant (LT) centers in SA. Concerns remain that there is an increased risk for individuals over 65 years of age, with underlying medical conditions, or for those who are immunocompromised. Therefore, the Saudi Association for the Study of Liver Diseases and Transplantation (SASLT) established an urgent task force to launch a statement that can be utilized by LT centers as a guidance in the management of patients with advanced liver disease from the time of LT listing to the post-operative care of transplanted patients."],"journal":"Saudi J Gastroenterol","authors":["Al-Judaibi, Bandar","Almaghrabi, Reem","Alghamdi, Mohammed","Al-Hamoudi, Waleed K","AlQahtani, Mohammed","Abaalkhail, Faisal","Shagrani, Mohammed","Sanai, Faisal M"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341229","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.4103/sjg.SJG_131_20","keywords":["covid-19","cirrhosis","liver transplant"],"locations":["Saudi Arabia","Saudi"],"countries":["Saudi Arabia"],"countries_codes":["SAU|Saudi Arabia"],"topics":["Prevention"],"weight":1,"_version_":1665351883934400513,"score":8.574329,"similar":[{"pmid":32330351,"title":"The impact of the COVID-19 outbreak on Liver Transplantation programmes in Northern Italy.","text":["The impact of the COVID-19 outbreak on Liver Transplantation programmes in Northern Italy.","In January 2020, Novel Coronavirus Disease 2019 (COVID-19) resulted in a global pandemic, creating uncertainty towards the management of Liver Transplantation (LT) programmes. Lombardy has been the most affected region in Italy: The current mortality rate of COVID-19 patients is 18,3% (10022 deaths) (April 10th) with hospitals in Lombardy having to expand the total number of ICU beds from 724 to 1381 to accommodate infected patients. There has been a drastic decrease in liver donors. From February 23(rd) until April 10th, 17 LTs were performed in Lombardy. Mean donor age was 49 years (range 18-74) whereas mean recipient age was 55 (13-69); mean MELD Score was 12 (6-24). All donors underwent screening for SARS CoV-2 prior to LT. Two patients tested positive after LT, and one patient died for COVID on POD 30. 16 patients are alive after an average of 30 days post LT (range 3-46). 10 patients have been discharged. This study has found no specific reason concerning the safety of recipients, to stop liver transplantation programmes. Several Key-lessons from our experience are reported. However, due to the complex circumstances which surround the viral outbreak, the cessation or a reduction in LT activity is a pragmatic requirement.","Am J Transplant","Maggi, Umberto","De Carlis, Luciano","Yiu, Daniel","Colledan, Michele","Regalia, Enrico","Rossi, Giorgio","Angrisani, Marco","Consonni, Dario","Fornoni, Gianluca","Piccolo, Giuseppe","DeFeo, Tullia Maria","32330351"],"abstract":["In January 2020, Novel Coronavirus Disease 2019 (COVID-19) resulted in a global pandemic, creating uncertainty towards the management of Liver Transplantation (LT) programmes. Lombardy has been the most affected region in Italy: The current mortality rate of COVID-19 patients is 18,3% (10022 deaths) (April 10th) with hospitals in Lombardy having to expand the total number of ICU beds from 724 to 1381 to accommodate infected patients. There has been a drastic decrease in liver donors. From February 23(rd) until April 10th, 17 LTs were performed in Lombardy. Mean donor age was 49 years (range 18-74) whereas mean recipient age was 55 (13-69); mean MELD Score was 12 (6-24). All donors underwent screening for SARS CoV-2 prior to LT. Two patients tested positive after LT, and one patient died for COVID on POD 30. 16 patients are alive after an average of 30 days post LT (range 3-46). 10 patients have been discharged. This study has found no specific reason concerning the safety of recipients, to stop liver transplantation programmes. Several Key-lessons from our experience are reported. However, due to the complex circumstances which surround the viral outbreak, the cessation or a reduction in LT activity is a pragmatic requirement."],"journal":"Am J Transplant","authors":["Maggi, Umberto","De Carlis, Luciano","Yiu, Daniel","Colledan, Michele","Regalia, Enrico","Rossi, Giorgio","Angrisani, Marco","Consonni, Dario","Fornoni, Gianluca","Piccolo, Giuseppe","DeFeo, Tullia Maria"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330351","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ajt.15948","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["Italy","Lombardy","Lombardy","Score"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664996914790137857,"score":567.201},{"pmid":32251003,"title":"Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis.","text":["Lung transplantation as therapeutic option in acute respiratory distress syndrome for COVID-19-related pulmonary fibrosis.","BACKGROUND: Critical patients with the 2019 coronavirus disease (COVID-19), even those whose nucleic acid test results had turned negative and those receiving maximal medical support, have been noted to progress to irreversible fatal respiratory failure. Lung transplantation (LT) as the sole therapy for end-stage pulmonary fibrosis related to acute respiratory distress syndrome has been considered as the ultimate rescue therapy for these patients. METHODS: From February 10 to March 10, 2020, three male patients were urgently assessed and listed for transplantation. After conducting a full ethical review and after obtaining assent from the family of the patients, we performed three LT procedures for COVID-19 patients with illness durations of >1 month and extremely high sequential organ failure assessment (SOFA) scores. RESULTS: Two of the three recipients survived post-LT and started participating in a rehabilitation program. Pearls of the LT team collaboration and perioperative logistics were summarized and continually improved. The pathological results of the explanted lungs were concordant with the critical clinical manifestation, and provided insight towards better understanding of the disease. Government health affair systems, virology detection tools, and modern communication technology all play key roles towards the survival of the patients and their rehabilitation. CONCLUSIONS: Lung transplantation can be performed in end-stage patients with respiratory failure due to COVID-19-related pulmonary fibrosis. If confirmed positive-turned-negative virology status without organ dysfunction, LT provided the final option for these patients to avoid certain death, with proper protection of transplant surgeons and medical staffs. By ensuring instant seamless care for both patients and medical teams, the goal of reducing the mortality rate and salvaging the lives of patients with COVID-19 can be attained.","Chin Med J (Engl)","Chen, Jing-Yu","Qiao, Kun","Liu, Feng","Wu, Bo","Xu, Xin","Jiao, Guo-Qing","Lu, Rong-Guo","Li, Hui-Xing","Zhao, Jin","Huang, Jian","Yang, Yi","Lu, Xiao-Jie","Li, Jia-Shu","Jiang, Shu-Yun","Wang, Da-Peng","Hu, Chun-Xiao","Wang, Gui-Long","Huang, Dong-Xiao","Jiao, Guo-Hui","Wei, Dong","Ye, Shu-Gao","Huang, Jian-An","Zhou, Li","Zhang, Xiao-Qin","He, Jian-Xing","32251003"],"abstract":["BACKGROUND: Critical patients with the 2019 coronavirus disease (COVID-19), even those whose nucleic acid test results had turned negative and those receiving maximal medical support, have been noted to progress to irreversible fatal respiratory failure. Lung transplantation (LT) as the sole therapy for end-stage pulmonary fibrosis related to acute respiratory distress syndrome has been considered as the ultimate rescue therapy for these patients. METHODS: From February 10 to March 10, 2020, three male patients were urgently assessed and listed for transplantation. After conducting a full ethical review and after obtaining assent from the family of the patients, we performed three LT procedures for COVID-19 patients with illness durations of >1 month and extremely high sequential organ failure assessment (SOFA) scores. RESULTS: Two of the three recipients survived post-LT and started participating in a rehabilitation program. Pearls of the LT team collaboration and perioperative logistics were summarized and continually improved. The pathological results of the explanted lungs were concordant with the critical clinical manifestation, and provided insight towards better understanding of the disease. Government health affair systems, virology detection tools, and modern communication technology all play key roles towards the survival of the patients and their rehabilitation. CONCLUSIONS: Lung transplantation can be performed in end-stage patients with respiratory failure due to COVID-19-related pulmonary fibrosis. If confirmed positive-turned-negative virology status without organ dysfunction, LT provided the final option for these patients to avoid certain death, with proper protection of transplant surgeons and medical staffs. By ensuring instant seamless care for both patients and medical teams, the goal of reducing the mortality rate and salvaging the lives of patients with COVID-19 can be attained."],"journal":"Chin Med J (Engl)","authors":["Chen, Jing-Yu","Qiao, Kun","Liu, Feng","Wu, Bo","Xu, Xin","Jiao, Guo-Qing","Lu, Rong-Guo","Li, Hui-Xing","Zhao, Jin","Huang, Jian","Yang, Yi","Lu, Xiao-Jie","Li, Jia-Shu","Jiang, Shu-Yun","Wang, Da-Peng","Hu, Chun-Xiao","Wang, Gui-Long","Huang, Dong-Xiao","Jiao, Guo-Hui","Wei, Dong","Ye, Shu-Gao","Huang, Jian-An","Zhou, Li","Zhang, Xiao-Qin","He, Jian-Xing"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251003","week":"202015|Apr 06 - Apr 12","doi":"10.1097/CM9.0000000000000839","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"_version_":1663352136275066882,"score":442.02197},{"pmid":32298473,"title":"Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.","text":["Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.","Coronavirus disease 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading throughout the world. Hospitals and healthcare providers are preparing for the anticipated surge in critically ill patients but few are wholly equipped to manage this new disease. We all must do our part to prepare our patients, clinics, and hospitals for the drastic changes necessary to mitigate the spread of SARS-CoV-2 or we risk overwhelming the capacity of our healthcare system. The goals of this document are to provide data on what is currently known about COVID-19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a template for the development of clinical recommendations and policies to mitigate the impact of the COVID-19 pandemic on liver patients and healthcare providers.","Hepatology","Fix, Oren K","Hameed, Bilal","Fontana, Robert J","Kwok, Ryan M","McGuire, Brendan M","Mulligan, David C","Pratt, Daniel S","Russo, Mark W","Schilsky, Michael L","Verna, Elizabeth C","Loomba, Rohit","Cohen, David E","Bezerra, Jorge A","Reddy, K Rajender","Chung, Raymond T","32298473"],"abstract":["Coronavirus disease 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading throughout the world. Hospitals and healthcare providers are preparing for the anticipated surge in critically ill patients but few are wholly equipped to manage this new disease. We all must do our part to prepare our patients, clinics, and hospitals for the drastic changes necessary to mitigate the spread of SARS-CoV-2 or we risk overwhelming the capacity of our healthcare system. The goals of this document are to provide data on what is currently known about COVID-19, and how it may impact hepatologists and liver transplant providers and their patients. Our aim is to provide a template for the development of clinical recommendations and policies to mitigate the impact of the COVID-19 pandemic on liver patients and healthcare providers."],"journal":"Hepatology","authors":["Fix, Oren K","Hameed, Bilal","Fontana, Robert J","Kwok, Ryan M","McGuire, Brendan M","Mulligan, David C","Pratt, Daniel S","Russo, Mark W","Schilsky, Michael L","Verna, Elizabeth C","Loomba, Rohit","Cohen, David E","Bezerra, Jorge A","Reddy, K Rajender","Chung, Raymond T"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298473","week":"202016|Apr 13 - Apr 19","doi":"10.1002/hep.31281","keywords":["sars-cov-2","cirrhosis","coronavirus","immunosuppression","transplantation"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664641388228116480,"score":360.80313},{"pmid":32277387,"title":"Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","text":["Management of COVID-19 in patients after liver transplantation: Beijing working party for liver transplantation.","Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic.","Hepatol Int","Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George","32277387"],"abstract":["Annually, around 850 liver transplantation is performed in Beijing, China. Recently, the new coronavirus pneumonia (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has affected nearly 200 countries worldwide. 2019-nCov can cause severe lung disease, multiple-organ damage, and significant mortalities. Liver transplant recipients, because of long-term oral immunosuppressant effects, may be more susceptible to 2019-nCoV infection and have a worse prognosis than the general population. It is urgent to set up guidelines for the prevention, diagnosis, and treatment of COVID-19 in liver transplant recipients. In this article, we reviewed the clinical aspects of 2019-nCoV infection, characteristics of liver transplant recipients, immunosuppressant usage, and potential drug interactions to provide recommendations to clinical staff managing liver transplant recipients during the COVID-19 epidemic."],"journal":"Hepatol Int","authors":["Liu, Hongling","He, Xi","Wang, Yudong","Zhou, Shuangnan","Zhang, Dali","Zhu, Jiye","He, Qiang","Zhu, Zhijun","Li, Guangming","Sun, Libo","Wang, Jianli","Cheng, Gregory","Liu, Zhenwen","Lau, George"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32277387","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10043-z","keywords":["2019-ncov","covid-19","liver transplantation","management"],"source":"PubMed","topics":["Prevention","Diagnosis","Treatment"],"weight":1,"locations":["Beijing","China","Beijing"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636943894315008,"score":357.26285},{"pmid":32270388,"title":"Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI).","text":["Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI).","The Liver Transplant Society of India (LTSI) has come up with guidelines for transplant centres across the country to deal with liver transplantation during this evolving pandemic of COVID-19 infection. The guidelines are applicable to both deceased donor as well as living donor liver transplants. In view of the rapidly changing situation of COVID-19 infection in India and worldwide, these guidelines will need to be updated according to the emerging data.","Hepatol Int","Saigal, Sanjiv","Gupta, Subash","Sudhindran, S","Goyal, Neerav","Rastogi, Amit","Jacob, Mathew","Raja, Kaiser","Ramamurthy, Anand","Asthana, Sonal","Dhiman, R K","Singh, Balbir","Perumalla, Rajasekhar","Malik, Ashish","Shanmugham, Naresh","Soin, Arvinder Singh","32270388"],"abstract":["The Liver Transplant Society of India (LTSI) has come up with guidelines for transplant centres across the country to deal with liver transplantation during this evolving pandemic of COVID-19 infection. The guidelines are applicable to both deceased donor as well as living donor liver transplants. In view of the rapidly changing situation of COVID-19 infection in India and worldwide, these guidelines will need to be updated according to the emerging data."],"journal":"Hepatol Int","authors":["Saigal, Sanjiv","Gupta, Subash","Sudhindran, S","Goyal, Neerav","Rastogi, Amit","Jacob, Mathew","Raja, Kaiser","Ramamurthy, Anand","Asthana, Sonal","Dhiman, R K","Singh, Balbir","Perumalla, Rajasekhar","Malik, Ashish","Shanmugham, Naresh","Soin, Arvinder Singh"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270388","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s12072-020-10041-1","source":"PubMed","topics":["Prevention"],"weight":1,"locations":["India"],"countries":["India"],"countries_codes":["IND|India"],"_version_":1664637315663790080,"score":324.97025}]}